Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,535 recalls, newest first.

Class II · Moderate risk

Sucralfate Tablets

CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Ongoing cGMP deviation Amerisource Health Services LLC NDC 60687-695-01 D-0598-2025
Class II · Moderate risk

Doxepin Hydrochloride Capsules

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Ongoing Nitrosamine impurity Alembic Pharmaceuticals Limited NDC 62332-637-31 D-0566-2025
Class II · Moderate risk

Lorazepam Injection

Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

Ongoing Impurity / degradation Hikma Pharmaceuticals USA Inc. NDC 0641-6044-25 D-0551-2025
Class II · Moderate risk

Belsomra (suvorexant)

Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep.

Ongoing Dissolution failure Merck & Co. Inc NDC 0006-0033-10 D-0584-2025

Recalls by year